Biomarkers in Precision Medicine: Unlocking the Future of Targeted Care

Biomarkers are revolutionizing how diseases are diagnosed, treated and managed by providers and their patients — especially in the age of precision medicine. This webinar brings together leading experts to explore how biomarkers are driving innovation in oncology, expanding into new therapeutic areas like autoimmune and infectious diseases and transforming care for neurodegenerative conditions such as Alzheimer’s.

The featured speakers will also discuss the economic impact of long-term care, the role of predictive analytics in identifying at-risk populations and the foundational strategies needed to ensure precision medicine is scalable, equitable and impactful across the healthcare ecosystem.

Join the featured speakers to:

• Examine real-world case studies showing how biomarker-driven strategies are influencing clinical decision-making across multiple therapeutic areas
• Gain perspectives on the economic and operational considerations of integrating biomarkers into healthcare systems at scale
• Explore collaborative models between researchers, payers and providers that are accelerating the adoption of precision medicine approaches

Register for this webinar to learn how biomarkers in precision medicine are driving innovation, improving patient outcomes and shaping the future of healthcare.

Speakers

(Moderator) Kevin Liang, Senior Vice President, Partnerships & Evidence Engine, Optum Life Sciences

Kevin oversees Partnerships for Optum Life Sciences, leading end-to-end execution of strategic partnerships with key clients as well as internal collaborations with other UnitedHealth Group businesses. He also leads Optum Evidence Engine, a consulting team supporting life sciences, diagnostics and digital health companies in their evidence generation and market access needs. Before joining OLS, Kevin held leadership roles in Optum Genomics and Optum Corporate Strategy.

Kevin began his career at Putnam Associates, a life sciences strategy consulting firm, where he advised global biotech and pharmaceutical clients on growth, portfolio management and pricing/reimbursement strategies across US and international markets. He has also worked in venture capital as well as early-stage healthcare services companies. Kevin holds a BA from the University of Pennsylvania and an MBA from Harvard Business School.

Message Presenter

Lou Brooks Jr., MA, Senior Vice President, Real-World Data and Analytics, Optum Life Sciences

Lou Brooks leads a team responsible for the development and deployment of health care data solutions that enable organizations to fuel their real-world evidence generation activities to support the development and commercialization of health care products and services. Over the past 25 years, he has led a variety of real-world data analytics teams, all focused on developing a better understanding of customer behavior across several industries, including telecommunications, pharmaceutical products and consumer packaged goods.

Lou has worked in the pharmaceutical industry since 1997. During his tenure at Optum, Lou has been focused on driving real-world-based data analytics projects using primarily claims and EMR data sources, as well as developing technology solutions that enable analytics to be packaged and executed more efficiently and effectively by a range of users. Lou has experience across a wide variety of therapeutic categories, including autoimmune disorders, diabetes, respiratory, CNS, oncology and cardiovascular conditions.

Message Presenter

Brady DeHart, Director, CNS and Mental Health, Optum Life Sciences

Brady DeHart is a Director or HEOR and the therapeutic lead for central nervous system and mental health in VES at Optum Life Sciences. Brady is responsible for conducting observational research studies using administrative claims, electronic health record/medical records, and other data sources. He has extensive experience as a health outcomes researcher and has expertise in health economics and outcomes research, behavioral health, substance abuse, retrospective and prospective studies, randomized control trials, and quantitative methods. He has also led multiple HEOR projects focused on evaluating the clinical utility of molecular test (i.e., precision medicine).

Before joining Optum, Brady was a Director of Research for HCA Healthcare, where he supervised the research activities of over 200 medical residents. Dehart received his PhD from Utah State University in Experimental Psychology and completed his postdoctoral work at Virginia Tech at the Addiction Recovery and Research Center. Brady has authored or co-authored over 90 publications and presentations, and his work has received popular press recognition including coverage in the Wall Street Journal.

Message Presenter

Stacey Brown, Market Access and Evidence Strategy Lead, Optum Evidence Engine

Stacey leads Market Access and Evidence Strategy for Optum Evidence Engine, overseeing all related engagements with diagnostic, pharma and medical device company clients. Stacey has over two decades of payer relations and market access experience in the molecular diagnostic space.

Prior to joining Optum, she spent many years at Myriad Genetics, in roles with increasing responsibility for securing coverage and reimbursement with regional, national and government-sponsored payers. Stacey went on to work at Foundation Medicine, leading Market Access and playing a significant role in the company, completing the FDA and CMS parallel review of the first comprehensive genomic profiling companion diagnostic assay. Stacey has also spent time at Sera Prognostics and GeneDx, as well as served as Co-Chair on the Access to Comprehensive Genomic Profiling Coalition, always working to increase access for precision medicine solutions.

Message Presenter